Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)

Part of paid clinical trials in Tampa, Florida.

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Study ID
NCT06423950
Status
Recruiting
Apply to this trial

Conditions

  • Pediatric Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Peds Evolutionary Tumor Board (pedsETB) — OTHER
    The pedsETB consists of evolutionary biologists, mathematicians, research scientists, statisticians, data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators. The pedsETB membership is inclusive of members from the participating institutions. The pedsETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The pedsETB will collect data through a chart review regarding adherence and results of ETB recommendation.

Study Details

To evaluate the ability of a multidisciplinary and multisite group, the Pediatric Evolutionary Tumor Board (pedsETB), to develop additional therapeutic strategies in patients without curative options or with suboptimal outcomes.

Key Dates

Start date
May 1, 2024
Status verified
Feb 2026
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
35 participants (estimated)

Arms

  • Arm: Participants Reviewed by ETB
    Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied. These ideas will be characterized (e.g. first strike-second strike, adaptive, novel sequential therapy, novel combination, novel dosing schedule, etc.).

Primary Outcome Measure

The feasibility of the pedsETB developing therapeutic strategies [ Time Frame: Baseline to up to 60 months from end of therapy ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Moffitt Cancer CenterTampaFlorida33612
Jessica Crimella
[email protected]
813-745-6250
Jonathan Metts, MD (PRINCIPAL_INVESTIGATOR)
Mark Robertson-Tessi, PhD (PRINCIPAL_INVESTIGATOR)
Joel S Brown, PhD (SUB_INVESTIGATOR)
Rikesh Makanji, MD (SUB_INVESTIGATOR)
Andriy Marusyk, PhD (SUB_INVESTIGATOR)
Alexander Anderson, PhD (SUB_INVESTIGATOR)

Find similar trials in Tampa, FL

By research site
Moffitt Cancer Center· Tampa, FL

Related Studies